Corporate Governance Overview

The Board of Directors of 9 Meters Biopharma, Inc. (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Mark Sirgo, PharmD - Chairman of the Board of Directors

Dr. Sirgo is Chief Executive Officer of Aruna Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to the Board from drug development through global product commercialization. Most recently, Dr. Sirgo served as President and CEO of BioDelivery Sciences International (BDSI:Nasdaq), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology.

John Temperato - President & Chief Executive Officer, Director

Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.

Nissim Darvish, M.D., PhD - Director

Dr. Darvish is a Senior Managing Director at OrbiMed Healthcare Fund Management, a veteran of the life science industry, and has 15 years of experience in covering medical technology development, corporate leadership and investment management. He spent 8 years with Pitango Venture Capital, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for 6 years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications.

Lorin Johnson, PhD - Director

Dr. Johnson joined our board of directors in January 2018. He is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company, and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as director of scientific operations and chief scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of Glycyx MOR, LTD and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, Intact Inc., a GI specialty drug delivery company based in Belmont, CA, Edesa Biotech (Nasdaq: EDSA) a dermatological and GI company based in Ontario, Canada, and Tumour Trace Ltd, a cancer diagnostic company based in Nottingham, UK. In addition to his career in industry, Dr. Johnson has served as an assistant professor of pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco. We believe that Dr. Johnson’s extensive experience in the pharmaceutical and life science industries, both as an executive and investor, qualifies him to serve on our board of directors.

Sandeep Laumas, M.D. - Director

Dr. Laumas served as our executive chairman since joining Private Innovate in 2014. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buy side as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a Managing Director of North Sound Capital from 2003 to 2007, where he was responsible for the global healthcare investment portfolio. In August 2007, Dr. Laumas founded Bearing Circle Capital, an investment vehicle, and has served as its Managing Director since such time. From February 2011 to 2012 he was a member of the board of directors of Super Religare Laboratories Limited, Southeast Asia’s largest clinical laboratory service company. Dr. Laumas serves as an independent director on the board of directors of Bioxcel Therapeutics, Inc. (Nasdaq: BTAI) and also served as a Director of Parkway Holdings Ltd. (acquired by IHH Healthcare for $3 Billion: Singapore: IHH) from May through August 2010. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana-Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine.

Michael T. Constantino – Director

Mr. Constantino joined our Board in June of 2020 and is a retired Ernst & Young LLP assurance partner with more than 30 years of experience.  Mr. Constantino has worked closely with companies across various development stages, from early start-up to mature Fortune 250 corporations, and assisted management teams and boards of directors with SEC compliance matters, global operations and strategic planning.  During his career, he worked with life science companies, CROs, technology, manufacturing and transportation firms.  Mike assisted clients with over 20 IPOs, debt offerings, M & A transactions, and private equity offerings, working closely with companies across the continuum from start-up to mature public entities while assisting management teams and boards with SEC compliance matters, Sarbanes-Oxley internal controls, global operations and strategic planning.  He is the Chair of the Board for the NC State Foundation, a member of the NC State Investment Fund Board and Chair of the Board of The Green Chair Project.  He has served as the Treasurer for the North Carolina Biotechnology Center, Chairman of the NC State Poole College of Management Board of Advisors, the Board of Directors and Treasurer for Rise Against Hunger (formerly, Stop Hunger Now), Board of Directors and Treasurer for the Council for Entrepreneurial Development, and Chairman and Treasurer for Southeastern Bio. Mike holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina CPA.

John Temperato

Chief Executive Officer

Ed Sitar

Chief Financial Officer

Sireesh Appajosyula, PharmD

SVP, Corporate Development & Operations

Patrick H. Griffin M.D. FACP

Chief Medical Officer

Nir Barak, M.D.

SVP, Scientific Affairs

 Board Member Independent Member Audit Committee Compensation Committee Nominating & Governance Committee
 Mark Sirgo,  PharmD I
 Nissim Darvish, M.D., Ph.D. I
 Lorin Johnson, PhD. I
 Sandeeep Laumas, M.D. I
 Michael T. Constantino I
         I = Independent Director          = Chairperson          = Member

Email Alerts     Print Page

Data may be delayed up to 15 minutes